Skip to main content
padlock icon - secure page this page is secure

Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase–deficient Renal Cell Carcinoma

Buy Article:

$62.00 + tax (Refund Policy)

Renal medullary carcinomas (RMCs) and collecting duct carcinomas (CDCs) are rare subsets of lethal high-stage, high-grade distal nephron-related adenocarcinomas with a predilection for the renal medullary region. Recent findings have established an emerging group of fumarate hydratase (FH)-deficient tumors related to hereditary leiomyomatosis and renal cell carcinoma (HLRCC-RCCs) syndrome within this morphologic spectrum. Recently developed, reliable ancillary testing has enabled consistent separation between these tumor types. Here, we present the clinicopathologic features and differences in the morphologic patterns between RMC, CDC, and FH-deficient RCC in consequence of these recent developments. This study included a total of 100 cases classified using contemporary criteria and ancillary tests. Thirty-three RMCs (SMARCB1/INI1-deficient, hemoglobinopathy), 38 CDCs (SMARCB1/INI1-retained), and 29 RCCs defined by the FH-deficient phenotype (FH/2SC+ or FH±/2SC+ with FH mutation, regardless of HLRCC syndromic stigmata/history) were selected. The spectrum of morphologic patterns was critically evaluated, and the differences between the morphologic patterns present in the 3 groups were analyzed statistically. Twenty-five percent of cases initially diagnosed as CDC were reclassified as FH-deficient RCC on the basis of our contemporary diagnostic approach. Among the different overlapping morphologic patterns, sieve-like/cribriform and reticular/yolk sac tumor–like patterns favored RMCs, whereas intracystic papillary and tubulocystic patterns favored FH-deficient RCC. The tubulopapillary pattern favored both CDCs and FH-deficient RCCs, and the multinodular infiltrating papillary pattern favored CDCs. Infiltrating glandular and solid sheets/cords/nested patterns were not statistically different among the 3 groups. Viral inclusion–like macronucleoli, considered as a hallmark of HLRCC-RCCs, were observed significantly more frequently in FH-deficient RCCs. Despite the overlapping morphology found among these clinically aggressive infiltrating high-grade adenocarcinomas of the kidney, reproducible differences in morphology emerged between these categories after rigorous characterization. Finally, we recommend that definitive diagnosis of CDC should only be made if RMC and FH-deficient RCC are excluded.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: FH-deficient renal cell carcinoma; collecting duct carcinoma; hereditary leiomyomatosis and renal cell carcinoma syndrome–associated renal cell carcinoma; morphology; renal medullary carcinoma

Document Type: Research Article

Affiliations: 1: Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 2: Departments of Pathology and Urology, VCU School of Medicine, Richmond, VA 3: Department of Pathology, Houston Methodist Hospital, Weill Medical College of Cornell University 4: Department of Pathology, University of Chicago, Chicago 5: Institute of Pathology, Friedrich-Alexander-University, Erlangen, Germany 6: William Beaumont Hospital, Royal Oak 7: Johns Hopkins Hospital, Baltimore, MD 8: Memorial Sloan Kettering Cancer Center, New York, NY 9: Indiana University School of Medicine, Indianapolis, IN 10: Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 11: Department of Pathology, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, UPMC Paris VI, Paris, France 12: Department of Pathology, AC Camargo Cancer Center, São Paulo 13: Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research Royal North Shore Hospital and University of Sydney 14: Charles University Hospital, Pilsen, Czech Republic 15: Brigham and Women’s Hospital, Boston, MA 16: Institute of Pathology, Kantonsspital St Gallen, St Gallen, Switzerland 17: Department of Pathology and Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 18: Douglass Hanly Moir Pathology, Sydney, NSW, Australia 19: Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH 20: Division of Pathological Anatomy, University of Florence, Florence, Italy 21: Emory University School of Medicine, Atlanta, GA 22: Department of Pathology, Loyola University, Maywood, IL 23: MD Anderson Cancer Center, Houston, TX 24: Anatomic Pathology, Mario Penna Institute, Hospital Luxemburgo, Belo Horizonte, Brazil 25: Institute of Anatomic Pathology, Piracicaba, Brazil 26: Calgary Laboratory Services, University of Calgary, Calgary, AB, Canada 27: Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, Department of Pathology and Laboratory Medicine and Urology, University of Tennessee Health Science Center, Memphis, TN

Publication date: March 1, 2018

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more